Phase 2 Portion Will Continue After Patients Have Completed Their Full Treatment Regimen of up to 17 doses of GEN-1 plus Standard Chemotherapy LAWRENCEVILLE, N.J. , Feb. 06, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation  (NASDAQ: CLSN) today announced that the independent Data Safety Monitoring

Company reaffirms its projection for second pre-planned interim efficacy analysis for Phase III OPTIMA Study in the second quarter of 2020 LAWRENCEVILLE, N.J. , Feb. 04, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , an oncology drug-development company, announces that Prof.

Memorandum of Understanding completed with Chinese government officials in the Yuhang district of Hangzhou , China’s biotech hub, to develop and commercialize innovative cancer therapies starting with ThermoDox ® . Agreement includes numerous financial and non-financial incentives including grants

  Non-Dilutive Funding Strengthens Balance Sheet; Proceeds Equate to More Than $0.08 Per Share Assures Funding Through Major Company Events; Company Provides Guidance on the Timing of Upcoming Development Milestones for the Phase III OPTIMA Study and the Phase I/II OVATION 2 Study LAWRENCEVILLE,

Independent Data Monitoring Committee (iDMC) Unanimously Recommends Continuation of Phase III OPTIMA Study at First Pre-Planned Efficacy Analysis Independent Data Safety Monitoring Board (DSMB) Unanimously Recommends Continuation of Phase I Portion of OVATION 2 Study         Strong Balance Sheet

Independent Analysis Confirms Increasing Heating Time + ThermoDox® Improves Tumor Uptake of Drug, which may be visualized by real-time fluorescence imaging Study Confirms that ThermoDox® Can Deliver Doxorubicin in Unprecedented Concentrations Directly into a Targeted Tumor  Comments on Common Stock

Company to Provide Clinical Development Update on its Phase III OPTIMA Study in Primary Liver Cancer and its Phase I/II OVATION 2 Study in Ovarian Cancer LAWRENCEVILLE, N.J. , Nov. 08, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a

GEN-1 Manufacturing Technology Transfer Successfully Produces High-Quality Affordable Investigational Product for Use in Clinical Trials LAWRENCEVILLE, N.J. , Nov. 05, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation  (NASDAQ: CLSN) today announced that the independent Data Safety Monitoring Board

The Data Monitoring Committee Signals that Patient Safety Data and Data Quality Meets Expectations and Company is to Proceed to Next Interim Analysis. The Pooled Progression-Free Survival (PFS) Data is Consistent with What Was Observed in the Pooled HEAT Study Subgroup Data.

  $2 Million in Additional NOL Sales are Available to the Company in 2020 Funding Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program LAWRENCEVILLE, N.J. , Oct. 01, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today